Clinical characteristics of rash and mucositis induced by Mycoplasma Pneumoniae in children

doi:10.3969/j.issn.1006-7795.2023.01.019

Abstract

Abstract: Objective To compare the clinical characteristics, treatment management and prognosis of Mycoplasma pneumoniae (MP) and drug-induced Stevens-Johnson syndrome (SJS) in children. Methods The clinical data of 94 children with SJS and 206 cases with erythema multiforme admitted to our hospital from 2010 to 2021 were retrospectively analyzed, and the control group consisting of MP positive children(n=26) and MP negative children(control group,n=31)with definite drug factors was compared and analyzed. Results In this study, MP positive SJS was more common in older children, and its incidence in children over 72 months was significantly higher than control group. Mucosal involvement was found in all patients, especially periocular mucosa (n=25, 96.2%). The main treatments were macrolide antibiotics (100%), corticosteroid (Cs) (84.6%) and intravenous immunoglobulin (IVIG) (26.9%). All patients with a severity-of-illness score for toxic epidermal necrolysis(SCORTEN) of 2 or above were treated with Cs. The proportion of IVIG was increased with the increase of SCORTEN. Conclusion MP-induced SJS is common in school-age children, with lower hospital stay,lower mortality, and better prognosis. The mucous membranes of the eye and mouth are often involved.

Key words: mycoplasma pneumonia, Stevens-Johnson syndrome, severity-of-illness score for toxic epidermal necrolysis(SCORTEN)

CLC Number:

R725.9

Jia Yanhong, Guo Fang, Wu Xiaoyuan, Li Wenhui. Clinical characteristics of rash and mucositis induced by Mycoplasma Pneumoniae in children[J]. Journal of Capital Medical University, 2023, 44(1): 131-136.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.01.019

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I1/131

References

[1] Waites K B, Talkington D F. Mycoplasma pneumoniae and its role as a human pathogen[J]. Clin Microbiol Rev, 2004, 17(4): 697-728.
[2] Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis[J]. Front Microbiol, 2016, 7: 23.
[3] Canavan T N, Mathes E F, Frieden I, et al. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review[J]. J Am Acad Dermatol, 2015, 72(2): 239-245.
[4] 国家卫生计生委合理用药专家委员会儿童用药专业组. 中国儿童肺炎支原体感染实验室诊断规范和临床实践专家共识(2019年)[J]. 中华儿科杂志, 2020, 58(5): 366-373.
[5] 中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 376-381.
[6] Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000, 115(2): 149-153.
[7] Sauteur P M M, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis—part of the Stevens-Johnson syndrome spectrum[J]. J Dtsch Dermatol Ges, 2012, 10(10): 740-746.
[8] Schalock P C, Dinulos J G H. Mycoplasma pneumoniae-induced cutaneous disease[J]. Int J Dermatol, 2009, 48(7): 673-681.
[9] Zhang L, Lai M M, Ai T, et al. Analysis of Mycoplasma pneumoniae infection among children with respiratory tract infections in hospital in Chengdu from 2014 to 2020[J]. Transl Pediatr, 2021, 10(4): 990-997.
[10] Kutty P K, Jain S, Taylor T H, et al. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia[J]. Clin Infect Dis, 2019, 68(1): 5-12.
[11] 张继燕, 陈艳萍. 重症渗出性多形红斑并发闭塞性细支气管炎5例临床分析及文献复习[J]. 中国中西医结合儿科学, 2020, 12(5): 413-417.
[12] Matar M, Kessler R, Olland A, et al. End-stage respiratory failure secondary to bronchiolitis obliterans syndrome induced by toxic epidermal necrosis, also known as lyell syndrome: a case report[J]. Transplant Proc, 2021, 53(4): 1371-1374.
[13] Sugino K, Hebisawa A, Uekusa T, et al. Bronchiolitis obliterans associated with Stevens-Johnson syndrome: histopathological bronchial reconstruction of the whole lung and immunohistochemical study[J]. Diagn Pathol, 2013, 8: 134.
[14] Thangaraju S, Bagri N, Gupta V, et al. Mycoplasma-induced rash and mucositis or Steven-Johnson syndrome[J]. Indian J Pediatr, 2021, 88(8): 802-804.
[15] Chen N, Li M. Case report and literature review: clinical characteristics of 10 children with Mycoplasma pneumoniae-induced rash and mucositis[J]. Front Pediatr, 2022, 10: 823376.
[16] Olson D, Watkins L K F, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-associated Stevens-Johnson syndrome[J]. Pediatrics, 2015, 136(2): e386-e394.
[17] Liew Y C C, Choo K J L, Oh C C, et al. Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: case-control analysis of a cohort managed in a specialized center[J]. J Am Acad Dermatol, 2022, 86(4): 811-817.
[18] Aoyama Y, Sawada F, Makino E, et al. Multiple drug sensitization syndrome: a distinct phenotype associated with unrecognized Mycoplasma pneumonia infection[J]. JAAD Case Rep, 2017, 3(4): 301-305.
[19] White K D, Chung W H, Hung S I, et al. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response[J]. J Allergy Clin Immunol, 2015, 136(2): 219-234.
[20] Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis—case report and systematic review of literature[J]. J Eur Acad Dermatol Venereol, 2015, 29(3): 595-598.
[21] Simecka J W, Ross S E, Cassell G H, et al. Interactions of mycoplasmas with B cells: antibody production and nonspecific effects[J]. Clin Infect Dis, 1993, 17(Suppl 1): S176-S182.
[22] Luo Z X, Luo J, Liu E M, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Pulmonol, 2014, 49(4): 377-380.
[23] Ye L P, Zhang C, Zhu Q X. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis[J]. PLoS One, 2016, 11(11): e0167120.
[24] Beheshti R, Cusack B. Atypical Stevens-Johnson syndrome associated with Mycoplasma pneumoniae[J]. Cureus, 2022, 14(2): e21825.
[25] Rajan T V. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation[J]. Trends Immunol, 2003, 24(7): 376-379.
[26] Lin C C, Chen C B, Wang C W, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies[J]. Expert Rev Clin Immunol, 2020, 16(4): 373-387.
[27] Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. J Dermatol, 2015, 42(1): 42-48.
[28] Tristani-Firouzi P, Petersen M J, Saffle J R, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children[J]. J Am Acad Dermatol, 2002, 47(4): 548-552.
[29] Prins C, Kerdel F A, Padilla R S, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases[J]. Arch Dermatol, 2003, 139(1): 26-32.
[30] Zhu Q Y, Ma L, Luo X Q, et al. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China[J]. J Burn Care Res, 2012, 33(6): e295-e308.
[31] Tsai T Y, Huang I H, Chao Y C, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis[J]. J Am Acad Dermatol, 2021, 84(2): 390-397.